Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 8:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: human lactoferrin Clear all
Not listed Not applicable Interventional

Use of Recombinant Human Lactoferrin in Long-Term Care Patients With Feeding Tubes With Clostridium Difficile.

NCT00377078
View directory record Official record
Conditions
Clostridium Difficile
Interventions
recombinant human lactoferrin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 14, 2006 · Synced Sep 9, 2026, 8:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Lactoferrin at Two Doses vs. Active Control on Markers of Immune Function

NCT06012669
View directory record Official record
Conditions
Immune Health
Interventions
High dose Human Lactoferrin, Low dose Human Lactoferrin, Active Control Bovine Lactoferrin
Dietary Supplement
Lead sponsor
Midwest Center for Metabolic and Cardiovascular Research
Other
Eligibility
18 Years to 45 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
2
States / cities
Miami, Florida • Port Saint Lucie, Florida
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Sep 9, 2026, 8:35 PM EDT
Completed Early Phase 1 Interventional Results available

Study of Biotene OralBalance Gel for Oral Care in Critically-Ill Mechanically Ventilated Neonates

NCT01314742
View directory record Official record
Conditions
Ventilator-associated Pneumonia
Interventions
Biotene OralBalance® gel, Sterile Water moisten cotton tipped applicator
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
7 Days and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Sep 9, 2026, 8:35 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Effera Human Lactoferrin at One Dose Compared to Placebo on Gut Permeability

NCT07035964
View directory record Official record
Conditions
Gut Permeability, Gut Health
Interventions
human lactoferrin, Placebo
Dietary Supplement
Lead sponsor
Helaina Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Sep 9, 2026, 8:35 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effera Dose Response: Women's Health

NCT07524270
View directory record Official record
Conditions
Womens Health, Menstrual Symptoms
Interventions
Effera® (human equivalent lactoferrin), Placebo
Dietary Supplement · Other
Lead sponsor
Helaina Inc.
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 9, 2026, 8:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Phase II Growth and Safety Study of an Infant Formula for Healthy Term Infants

NCT04593147
View directory record Official record
Conditions
Infant Development
Interventions
BBN, Brand
Other
Lead sponsor
Building Block Nutritionals, LLC
Industry
Eligibility
1 Day to 14 Days
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 14, 2021 · Synced Sep 9, 2026, 8:35 PM EDT
Completed Phase 2 Interventional Results available

Effects of rhLactoferrin on Chronic Inflammation in the Elderly

NCT02968992
View directory record Official record
Conditions
Inflammation, Cognitive Deterioration
Interventions
rhLactoferrin, Placebo
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
70 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Sep 9, 2026, 8:35 PM EDT
Completed Phase 2 Interventional

Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma

NCT00095186
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Recombinant Human Lactoferrin
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
6
States / cities
Los Angeles, California • Stanford, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2008 · Synced Sep 9, 2026, 8:35 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer

NCT00707304
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Talactoferrin, Placebo
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older
Enrollment
742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
29
States / cities
Casa Grande, Arizona • Tucson, Arizona • Aurora, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2012 · Synced Sep 9, 2026, 8:35 PM EDT
Not listed Phase 3 Interventional

Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer

NCT00706862
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Talactoferrin, Placebo
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
6
States / cities
Duarte, California • Chicago, Illinois • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Sep 9, 2026, 8:35 PM EDT
Not listed Phase 1Phase 2 Interventional

Study of Talactoferrin Oral Solution for Nosocomial Infection in Preterm Infants

NCT00854633
View directory record Official record
Conditions
Nosocomial Infections
Interventions
Talactoferrin, Placebo
Drug
Lead sponsor
Agennix
Industry
Eligibility
1 Minute to 24 Hours
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
4
States / cities
Los Angeles, California • Louisville, Kentucky • Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Sep 9, 2026, 8:35 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Pilot Study to Evaluate the Ability of Lactoferrin to Modulate Iron Homeostasis and Exercise Performance in Exercising Females

NCT07546591
View directory record Official record
Conditions
Iron Deficiencies, Low Ferritin, Iron Deficiency, Exercise Performance of Fit Athletes
Interventions
Lactoferrin 100 mg, Lactoferrin 300 mg, Iron Supplementation (5 mg)
Dietary Supplement
Lead sponsor
Lindenwood University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 9, 2026, 8:35 PM EDT
Terminated Phase 1 Interventional

Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer

NCT01528137
View directory record Official record
Conditions
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IV Non-small Cell Lung Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer
Interventions
talactoferrin, laboratory biomarker analysis
Biological · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2016 · Synced Sep 9, 2026, 8:35 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Recombinant Human Lactoferrin to Treat Severe Sepsis

NCT00630656
View directory record Official record
Conditions
Severe Sepsis
Interventions
Talactoferrin alfa, Placebo
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
27
States / cities
Loma Linda, California • Sacramento, California • Sylmar, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2011 · Synced Sep 9, 2026, 8:35 PM EDT
Suspended Phase 2Phase 3 Interventional

Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis

NCT01273779
View directory record Official record
Conditions
Severe Sepsis
Interventions
Talactoferrin alfa, Placebo
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older
Enrollment
1,280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
34
States / cities
Birmingham, Alabama • Mobile, Alabama • Maricopa, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Sep 9, 2026, 8:35 PM EDT